首页> 美国卫生研究院文献>PLoS Pathogens >Lactobacillus gasseri ATCC33323 affects the intestinal mucosal barrier to ameliorate DSS-induced colitis through the NR1I3-mediated regulation of E-cadherin
【2h】

Lactobacillus gasseri ATCC33323 affects the intestinal mucosal barrier to ameliorate DSS-induced colitis through the NR1I3-mediated regulation of E-cadherin

机译:加氏乳杆菌 ATCC33323 通过 NR1I3 介导的 E-钙粘蛋白调节影响肠道粘膜屏障以改善 DSS 诱导的结肠炎

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inflammatory bowel disease (IBD) is an immune system disorder primarily characterized by colitis, the exact etiology of which remains unclear. Traditional treatment approaches currently yield limited efficacy and are associated with significant side effects. Extensive research has indicated the potent therapeutic effects of probiotics, particularly Lactobacillus strains, in managing colitis. However, the mechanisms through which Lactobacillus strains ameliorate colitis require further exploration. In our study, we selected Lactobacillus gasseri ATCC33323 from the intestinal microbiota to elucidate the specific mechanisms involved in modulation of colitis. Experimental findings in a DSS-induced colitis mouse model revealed that L. gasseri ATCC33323 significantly improved physiological damage in colitic mice, reduced the severity of colonic inflammation, decreased the production of inflammatory factors, and preserved the integrity of the intestinal epithelial structure and function. It also maintained the expression and localization of adhesive proteins while improving intestinal barrier permeability and restoring dysbiosis in the gut microbiota. E-cadherin, a critical adhesive protein, plays a pivotal role in this protective mechanism. Knocking down E-cadherin expression within the mouse intestinal tract significantly attenuated the ability of L. gasseri ATCC33323 to regulate colitis, thus confirming its protective role through E-cadherin. Finally, transcriptional analysis and in vitro experiments revealed that L. gasseri ATCC33323 regulates CDH1 transcription by affecting NR1I3, thereby promoting E-cadherin expression. These findings contribute to a better understanding of the specific mechanisms by which Lactobacillus strains alleviate colitis, offering new insights for the potential use of L. gasseri as an alternative therapy for IBD, particularly in dietary supplementation.
机译:炎症性肠病 (IBD) 是一种以结肠炎为主要特征的免疫系统疾病,其确切病因尚不清楚。传统的治疗方法目前疗效有限,并且与显着的副作用相关。广泛的研究表明,益生菌,尤其是乳酸菌菌株,在控制结肠炎方面具有强大的治疗作用。然而,乳酸菌菌株改善结肠炎的机制需要进一步探索。在我们的研究中,我们从肠道微生物群中选择了加氏乳杆菌 ATCC33323 来阐明结肠炎调节所涉及的特定机制。在 DSS 诱导的结肠炎小鼠模型中的实验结果表明,L. gasseri ATCC33323显著改善结肠炎小鼠的生理损伤,降低结肠炎症的严重程度,减少炎症因子的产生,并保持肠上皮结构和功能的完整性。它还维持了粘附蛋白的表达和定位,同时提高了肠道屏障通透性并恢复了肠道菌群中的生态失调。E-钙粘蛋白是一种关键的粘附蛋白,在这种保护机制中起着关键作用。敲低小鼠肠道内 E-钙粘蛋白的表达显着减弱了 L. gasseri ATCC33323 调节结肠炎的能力,从而证实了其通过 E-钙粘蛋白的保护作用。最后,转录分析和体外实验显示,L. gasseri ATCC33323通过影响 NR1I3 来调节 CDH1 转录,从而促进 E-cadherin 表达。这些发现有助于更好地了解乳酸菌菌株缓解结肠炎的具体机制,为加氏乳杆菌作为 IBD 替代疗法的潜在用途提供了新的见解,特别是在膳食补充剂中。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号